Skip to main content
Rogier Sanders

Rogier Sanders

Professor of Virology, specialty Experimental Vaccinology
Amsterdam UMC, The Netherlands

Rogier Sanders studied medical biology at the University of Amsterdam and the Rockefeller University in New York. In 2004, he obtained his PhD (cum laude) from the University from Amsterdam. Rogier is currently a Professor of Virology, specializing in experimental vaccinology, at the Academic Medical Center of the University of Amsterdam and holds an affiliate faculty position at Weill Medical College of Cornell University in New York City.

His research focuses on viral glycoprotein vaccines, in particular those based on native-like trimers. Several of Rogier’s HIV-1 envelope trimers are now in Phase I clinical trials as candidate vaccines and Rogier’s proline stabilization of HIV-1 envelope trimers has inspired COVID-19 vaccines currently in use worldwide.

Rogier has received several prestigious grants, such as the Veni, Vidi and Vici grants from the Netherlands Organization for Scientific Research and a Starting Investigator grant from the European Research Council. He leads and/or participates in various research consortia funded by the EU, NIH/NIAID and the Bill & Melinda Gates Foundation. Rogier has authored or co-authored more than 200 articles in scientific journals, including Nature, Science and Cell. His H-index is 64 and his papers have been cited over 14,000 times.

In 2011, he received the Dutch Prize for Biochemistry and Molecular Biology. He shared the top position in a top-10 list of “hottest authors” in HIV and AIDS research, compiled by Thomson Reuters, in 2013-2015..

The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.